CA2885570C - Procedes de traitement du trouble de stress post traumatique - Google Patents

Procedes de traitement du trouble de stress post traumatique Download PDF

Info

Publication number
CA2885570C
CA2885570C CA2885570A CA2885570A CA2885570C CA 2885570 C CA2885570 C CA 2885570C CA 2885570 A CA2885570 A CA 2885570A CA 2885570 A CA2885570 A CA 2885570A CA 2885570 C CA2885570 C CA 2885570C
Authority
CA
Canada
Prior art keywords
nutritional supplement
mmol
arginine
lysine
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2885570A
Other languages
English (en)
Other versions
CA2885570A1 (fr
Inventor
Amy L. Heaton
Mitchell K. Friedlander
Dennis W. Gay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quality IP Holdings LLC
Original Assignee
Quality IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/623,101 external-priority patent/US9198889B2/en
Priority claimed from US13/623,097 external-priority patent/US8808763B2/en
Application filed by Quality IP Holdings LLC filed Critical Quality IP Holdings LLC
Priority to CA3145082A priority Critical patent/CA3145082C/fr
Publication of CA2885570A1 publication Critical patent/CA2885570A1/fr
Application granted granted Critical
Publication of CA2885570C publication Critical patent/CA2885570C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Il est décrit un supplément nutritif et son utilisation par voie buccale pour améliorer l'efficacité du sommeil chez un humain en santé, le supplément comprenant : L-arginine; Oxo-proline; L-lysine; N-acétyle L-cystéine; L-glutamine; et de la poudre de parties aériennes d'herbe Schizonepeta.
CA2885570A 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique Active CA2885570C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3145082A CA3145082C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/623,101 US9198889B2 (en) 2012-09-19 2012-09-19 Methods for treating post-traumatic stress disorder
US13/623,101 2012-09-19
US13/623,097 2012-09-19
US13/623,097 US8808763B2 (en) 2012-09-19 2012-09-19 Methods for improving sleep efficiency in healthy human beings
PCT/US2013/060672 WO2014047323A1 (fr) 2012-09-19 2013-09-19 Procédés de traitement du trouble de stress post traumatique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3145082A Division CA3145082C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Publications (2)

Publication Number Publication Date
CA2885570A1 CA2885570A1 (fr) 2014-03-27
CA2885570C true CA2885570C (fr) 2022-03-15

Family

ID=50341940

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3145082A Active CA3145082C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique
CA2885570A Active CA2885570C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3145082A Active CA3145082C (fr) 2012-09-19 2013-09-19 Procedes de traitement du trouble de stress post traumatique

Country Status (2)

Country Link
CA (2) CA3145082C (fr)
WO (1) WO2014047323A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions

Also Published As

Publication number Publication date
CA2885570A1 (fr) 2014-03-27
CA3145082C (fr) 2024-02-13
CA3145082A1 (fr) 2014-03-27
WO2014047323A1 (fr) 2014-03-27

Similar Documents

Publication Publication Date Title
US9198889B2 (en) Methods for treating post-traumatic stress disorder
Boivin et al. Working on atypical schedules
US10369182B2 (en) Compositions and methods for treating insomnia and other sleep related disorders
US8808763B2 (en) Methods for improving sleep efficiency in healthy human beings
JP2016516782A (ja) 心的外傷後ストレス障害を処置するための方法
MX2014010939A (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
Sydenstricker et al. The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders
JP7757450B2 (ja) エルゴチオネイン又はその塩を含有する睡眠改善用組成物
Pabis et al. Pharmacotherapy of aggressive behavior
US20130017278A1 (en) Composition and method for improving brain function
US8987232B2 (en) Agent for ameliorating brain hypofunction
Reid et al. Circadian rhythm sleep disorders
JP2014065695A (ja) ロイシンを含有する睡眠改善剤
CA2885570C (fr) Procedes de traitement du trouble de stress post traumatique
US10583095B2 (en) Method for stress management and overall health status improvement and compositions used therein
US20240197704A1 (en) Treatment methods and compositions comprising perampanel
Dighikar et al. A Rare Case of Wilson’s Disease in a 17 Years Old Girl
JP2014065694A (ja) アスパラギン酸を含有する睡眠改善剤
JP7185260B2 (ja) 悪夢障害の治療用医薬組成物
JP2009539941A (ja) Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
CA3053916C (fr) Composition anti-psychotique et methodes de traitement
KR20260050074A (ko) 포포나무 열매 추출물을 유효성분으로 포함하는 수면장애 또는 불면증의 예방, 개선 또는 치료용 조성물
EP3478279A1 (fr) Combinaisons de bêta-glycolipides et de 4-[(2-amino-3,5-dibromophényl)méthylamino]cyclohexan-1-ol, compositions et utilisations de celles-ci dans le traitement de troubles associés au repliement erroné des protéines et aux agrégations de protéines
Hoffer Allergy, depression and tricyclic antidepressants
RU2545709C1 (ru) Способ коррекции психических расстройств у больных с глиальными опухолями головного мозга различной локализации в раннем послеоперационном периоде

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180914

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250912